limited to, statements concerning: BioNTech's efforts to combat 
COVID-19; the collaboration between BioNTech and Pfizer to develop a 
COVID-19 vaccine (including a potential second booster dose of BNT162b2 
and/or a potential booster dose of a variation of BNT162b2 having a 
modified mRNA sequence); our expectations regarding the potential 
characteristics of BNT162b2 in our clinical trials and/or in commercial 
use based on data observations to date; the ability of BNT162b2 to 
prevent COVID-19 caused by emerging virus variants; the expected time 
point for additional readouts on efficacy data of BNT162b2 in our 
clinical trials; the nature of the clinical data, which is subject to 
ongoing peer review, regulatory review and market interpretation; the 
timing for submission of data for, or receipt of, any marketing approval 
or Emergency Use Authorization; our contemplated shipping and storage 
plan, including our estimated product shelf life at various 
temperatures; and the ability of BioNTech to supply the quantities of 
BNT162 to support clinical development and market demand, including our 
production estimates for 2021. Any forward-looking statements in this 
press release are based on BioNTech current expectations and beliefs of 
future events, and are subject to a number of risks and uncertainties 
that could cause actual results to differ materially and adversely from 
those set forth in or implied by such forward-looking statements. These 
risks and uncertainties include, but are not limited to: the ability to 
meet the pre-defined endpoints in clinical trials; competition to create 
a vaccine for COVID-19; the ability to produce comparable clinical or 
other results, including our stated rate of vaccine effectiveness and 
safety and tolerability profile observed to date, in the remainder of 
the trial or in larger, more diverse populations upon commercialization; 
the ability to effectively scale our productions capabilities; and other 
potential difficulties. 
 
   For a discussion of these and other risks and uncertainties, see 
BioNTech's Quarterly Report for the Three and Nine Months Ended 
September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 
6-K filed with the SEC on November 10, which is available on the SEC's 
website at www.sec.gov. All information in this press release is as of 
the date of the release, and BioNTech undertakes no duty to update this 
information unless required by law. 
 
   Pfizer Contacts: 
 
   Media Relations 
 
   Jerica Pitts 
 
   +1 (347) 224-9084 
 
   https://www.globenewswire.com/Tracker?data=3Rj_Xr3BOIuLU0fkWOvJfZHe2it459Ee4AmbYVcp6Bzz3kknotPFHYwW5zpRLSNvcGZR9DPx4xCU6-Vmzxpfz4FY3gD4Z5fiXwhh3XeKUpY= 
Jerica.Pitts@pfizer.com 
 
   Investor Relations 
 
   Chuck Triano 
 
   +1 (212) 733-3901 
 
   https://www.globenewswire.com/Tracker?data=IPcwaQ62EdKUmOL_NGsglDPnmSpz1ROWr9dU0KALj96yrjSbDYCEbGHYtzVwhBGf6lq_0WU0PolcZ-SVGsWbPkxUmuWbmo9Y4hqJqIltm0dHHus2sor5AKZaYMQGo8oA 
Charles.E.Triano@Pfizer.com 
 
   BioNTech Contacts: 
 
   Media Relations 
 
   Jasmina Alatovic 
 
   +49 (0)6131 9084 1513 
 
   https://www.globenewswire.com/Tracker?data=NNVnhD5aX6SuoUH5Fquk1j2b0PiAClD1EKfNbRld5zbZGO9RpkngkuGq_krkrgO2uzv3P2NssGLhBymHEk5y1X3gLuEEi5P6n5RzdDrAq2c= 
Media@biontech.de 
 
   Investor Relations 
 
   Sylke Maas, Ph.D. 
 
   +49 (0)6131 9084 1074 
 
   https://www.globenewswire.com/Tracker?data=dIRG-CpsH6u8skluKtchIaYQnguj8h9ekVn20f_l775T02DfVjJFeCy5FseBLcBsNM5a_ZApTWqAzDlOPNBZiwjav1QZagd_iPWKLjggMso= 
Investors@biontech.de

(END) Dow Jones Newswires

February 25, 2021 06:45 ET (11:45 GMT)